In the first year of the "thirteenth-five" plan, the Institut Pasteur of Shanghai(IPS)implemented the innovation-driven development strategy and the Pioneer Initiative of the Chinese Academy of Sciences (CAS), and made a significant breakthrough in the fields of institutional innovation, scientific and technological achievements, and international cooperation.
IPS is an independent, non-profit life sciences institute that addresses public health issues in China and the Asian region. IPS creates synergies between the Institut Pasteur and CAS networks, leveraging all the assets of Shanghai, one of the leading businesses and technology hubs in Asia. Our scientists are engaged in a broad range of infectious diseases research programs ranging from viral hepatitis, HIV/AIDS, viral respiratory infections, virus-induced cancers and other major human pathologies like malaria and tuberculosis. Our activities are focused on the studiesof pathogenesis of infections, ranging from molecular mechanisms of host/pathogen interactions to immune responses counteracting with the pathogens to confer protection. Moreover, we are also involved in the development of countermeasures against infections with a predominant effort on the development of vaccines and the identification of low molecular weight compounds of therapeutic interests.
In 2016, the innovation capability for science and technology continued to increase. The Institute had 138 projects (including 36 newly commenced), 33 patents, and 89 published papers.
In 2016, the Institute's basic and applied research teams were complementary and coordinated, and they made remarkable technology transfer achievements in the field of infectious diseases. IPS signed over 20 technology transfer agreements including know-how transfers, patent licensing, technology trade-in investments and cooperation developments. The total contract amount reached 100 million RMB.
In 2016, under the framework of the Chinese “One Belt One Road”initiative, IPS made full use of the research resources of Institut Pasteur International Network (IPIN) and cooperated actively with institutions of IPIN around the world. To deepen the degree of international cooperation, IPSlaunched multinational cooperations, such as the “Asian-African Rainbow Initiative” and the “Gold Mine Project”. These ambitious projects included many organizations and agencies, focusing on research for preparedness for the potential global outbreaks. These projects expecting to bethe global promoter and leader for One Health obtained strong supports from CASheadquarter, the Ministry of Science and Technology and Shanghai Municipality.
Overall, our initiatives working towards an extended and intensified international projection converge to comply with the goals of the Pasteur Institutes for the promotion of multi-centre international collaborations along with China's “One Belt, One Road” strategy.
We are confident that in 2017 the on-going IPSscientific strategies and projects will successfully develop and the objectives created by the new direction team will be reached.
TANG Hong Fernando ARENZANA
Director General Co-director for Scientific Research